CAS OpenIR  > 生化工程国家重点实验室
Intravenous immunoglobulin improves glucose control and beta-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers
Zhang, Yue1,2; Yu, Xiao-lin1; Zhu, Jie1; Liu, Shu-ying1; Liu, Xiang-meng1; Dong, Quan-xiu1; Chai, Jia-qian2; Liu, Rui-tian1
2018
发表期刊INTERNATIONAL IMMUNOPHARMACOLOGY
ISSN1567-5769
卷号54页码:145-152
摘要Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by beta-cell loss, insulin resistance, islet inflammation and amyloid deposits derived from islet amyloid polypeptide (IAPP). Reducing toxic IAPP oligomers and inhibiting islet inflammation may provide therapeutic benefit in treating T2DM. Intravenous immunoglobulin (IVIg) is an efficient anti-inflammatory and immunomodulatory agent for the treatment of several autoinunune or inflammatory neurological diseases. However, whether Wig has therapeutic potential on T2DM remains unclear. In present study, we showed that IVIg treatment significantly improved glucose control and insulin sensitivity, and prevented-cell apoptosis by lowering toxic IAPP oligomer levels, attenuating islet inflammation and activating autophagy in human IAPP transgenic mouse model. These results suggest that IVIg is a promising therapeutic potential for T2DM treatment.
关键词Type 2 Diabetes Mellitus Intravenous Immunoglobulin Islet Amyloid Polypeptide Islet Inflammation Toxic Oligomer
文章类型Article
WOS标题词Science & Technology ; Life Sciences & Biomedicine
DOI10.1016/j.intimp.2017.11.012
收录类别SCI
语种英语
关键词[WOS]DIABETES-MELLITUS ; TARGETING INFLAMMATION ; INSULIN-RESISTANCE ; HUMAN-DISEASE ; KAPPA-B ; TOXICITY ; ACTIVATION ; MECHANISM ; ALZHEIMERS ; MANAGEMENT
WOS研究方向Immunology ; Pharmacology & Pharmacy
WOS类目Immunology ; Pharmacology & Pharmacy
项目资助者National Natural Science Foundation of China(81371208 ; National Science and Technology Major Projects of New Drugs(2014ZX09102045-005 ; Strategic Priority Research Program of the Chinese Academy of Sciences(XDA12040215) ; 81402837) ; 2014ZX09102041-007)
WOS记录号WOS:000423887900019
引用统计
文献类型期刊论文
条目标识符http://ir.ipe.ac.cn/handle/122111/24094
专题生化工程国家重点实验室
作者单位1.Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China
2.Shandong Agr Univ, Tai An 271018, Shandong, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Yue,Yu, Xiao-lin,Zhu, Jie,et al. Intravenous immunoglobulin improves glucose control and beta-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers[J]. INTERNATIONAL IMMUNOPHARMACOLOGY,2018,54:145-152.
APA Zhang, Yue.,Yu, Xiao-lin.,Zhu, Jie.,Liu, Shu-ying.,Liu, Xiang-meng.,...&Liu, Rui-tian.(2018).Intravenous immunoglobulin improves glucose control and beta-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers.INTERNATIONAL IMMUNOPHARMACOLOGY,54,145-152.
MLA Zhang, Yue,et al."Intravenous immunoglobulin improves glucose control and beta-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers".INTERNATIONAL IMMUNOPHARMACOLOGY 54(2018):145-152.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Yue]的文章
[Yu, Xiao-lin]的文章
[Zhu, Jie]的文章
百度学术
百度学术中相似的文章
[Zhang, Yue]的文章
[Yu, Xiao-lin]的文章
[Zhu, Jie]的文章
必应学术
必应学术中相似的文章
[Zhang, Yue]的文章
[Yu, Xiao-lin]的文章
[Zhu, Jie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。